CN104781276A - 肽-树枝状聚合物结合物及其用途 - Google Patents

肽-树枝状聚合物结合物及其用途 Download PDF

Info

Publication number
CN104781276A
CN104781276A CN201380053703.4A CN201380053703A CN104781276A CN 104781276 A CN104781276 A CN 104781276A CN 201380053703 A CN201380053703 A CN 201380053703A CN 104781276 A CN104781276 A CN 104781276A
Authority
CN
China
Prior art keywords
compound
group
dendrimer
cys
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380053703.4A
Other languages
English (en)
Chinese (zh)
Inventor
米歇尔·德默勒
阿兰·拉罗克
杨高强
萨斯米塔·塔里帕西
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Angiochem Inc
Original Assignee
Angiochem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angiochem Inc filed Critical Angiochem Inc
Publication of CN104781276A publication Critical patent/CN104781276A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/595—Polyamides, e.g. nylon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/641—Branched, dendritic or hypercomb peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • C07K14/8117—Bovine/basic pancreatic trypsin inhibitor (BPTI, aprotinin)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201380053703.4A 2012-08-14 2013-08-14 肽-树枝状聚合物结合物及其用途 Pending CN104781276A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261682991P 2012-08-14 2012-08-14
US61/682,991 2012-08-14
PCT/CA2013/050621 WO2014026283A1 (en) 2012-08-14 2013-08-14 Peptide-dendrimer conjugates and uses thereof

Publications (1)

Publication Number Publication Date
CN104781276A true CN104781276A (zh) 2015-07-15

Family

ID=50101156

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380053703.4A Pending CN104781276A (zh) 2012-08-14 2013-08-14 肽-树枝状聚合物结合物及其用途

Country Status (7)

Country Link
US (1) US9687561B2 (enExample)
EP (1) EP2885318A4 (enExample)
JP (1) JP2015526434A (enExample)
CN (1) CN104781276A (enExample)
AU (1) AU2013302270A1 (enExample)
CA (1) CA2881602A1 (enExample)
WO (1) WO2014026283A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106854231A (zh) * 2015-12-09 2017-06-16 中国科学院大连化学物理研究所 一种硫巯化多肽的富集方法
CN117363697A (zh) * 2023-10-10 2024-01-09 上海烈冰生物医药科技有限公司 一种用于核酸捕获的高密度探针磁珠制备方法

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2233156T3 (da) 2005-07-15 2013-08-05 Angiochem Inc Anvendelse af aprotininpolypeptider som bærere i farmaceutiske konjugater
CA2740316A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Conjugates of glp-1 agonists and uses thereof
CA2745524C (en) 2008-12-05 2020-06-09 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
CA2881602A1 (en) 2012-08-14 2014-02-20 Angiochem Inc. Peptide-dendrimer conjugates and uses thereof
WO2016090495A1 (en) * 2014-12-11 2016-06-16 Angiochem Inc. TARGETED α-L-IDURONIDASE CONJUGATES AND USES THEREOF
FI3650459T3 (fi) 2015-02-24 2023-11-28 Hope City Kemiallisesti koodattuja spatiaalisesti osoitettuja kirjastojen seulonta-alustoja
DK3307326T3 (da) 2015-06-15 2020-10-19 Angiochem Inc Fremgangsmåder til behandling af leptomeningeal karcinomatose
JP7041616B2 (ja) 2015-09-14 2022-03-24 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム リポカチオン性デンドリマーおよびその使用
CA3003628C (en) * 2015-10-29 2022-05-03 The Johns Hopkins University Dendrimer compositions and use in treatment of necrotizing enterocolitis and other gastrointestinal disorders
US11530243B2 (en) * 2016-02-18 2022-12-20 Veiove Animal Health Inc. Non-cleavable substance P conjugates and methods of use thereof
PL417159A1 (pl) * 2016-05-11 2017-11-20 Instytut Biologii Doświadczalnej Im. Marcelego Nenckiego Koniugaty białka prionowego z dendrymerami do zastosowania w leczeniu choroby Alzheimera
DK3458074T3 (da) * 2016-05-16 2024-07-29 Univ Texas COMPOSITIONS FOR THE DELIVERY OF tRNA AS NANOPARTICLES AND METHODS OF USE THEREWITH
CN106279635B (zh) * 2016-08-10 2019-01-25 同济大学 类抗菌肽和囊泡及其制备方法和应用
ES2677242B1 (es) * 2017-01-31 2019-03-27 Univ Alcala Henares Nanoconjugados formados por moléculas dendríticas y péptidos como agentes antitumorales frente al cáncer
JP7178108B2 (ja) 2017-04-27 2022-11-25 ザ・ジョンズ・ホプキンス・ユニバーシティー 血管造影において使用するためのデンドリマー組成物
CA3082121C (en) 2017-11-10 2023-01-24 The Johns Hopkins University Dendrimer delivery system and methods of use thereof
US12357580B2 (en) 2018-06-19 2025-07-15 The Board Of Regents Of The University Of Texas System Lipid nanoparticle compositions for delivery of mRNA and long nucleic acids
AU2019336679B2 (en) 2018-09-04 2025-05-29 The Board Of Regents Of The University Of Texas System Compositions and methods for organ specific delivery of nucleic acids
GB2600800B (en) 2018-09-04 2023-08-16 Univ Texas Compositions and methods for organ specific delivery of nucleic acids
WO2020113036A2 (en) * 2018-11-28 2020-06-04 Promega Corporation Reactive peptide labeling
CN110170055A (zh) * 2019-06-04 2019-08-27 哈尔滨理工大学 一种新型双重脑缺血靶向纳米载体材料的制备方法
WO2021046307A1 (en) * 2019-09-04 2021-03-11 North Carolina State University Hybridized poly(amidoamine)-amino acid dendrimers
IL293606A (en) 2019-12-04 2022-08-01 Ashvattha Therapeutics Inc Dendrimer preparations and methods of administering a drug to the eye
IL297129A (en) * 2020-04-06 2022-12-01 Tiba Biotech Llc leading to efficient application of nucleic acids
US20220226465A1 (en) 2021-01-18 2022-07-21 ConserV Bioscience Coronavirus Immunogenic Compositions, Methods and Uses Thereof
WO2024029242A1 (ja) * 2022-08-05 2024-02-08 一丸ファルコス株式会社 新規ｌｒｐ１結合ペプチド
WO2025096681A1 (en) 2023-10-31 2025-05-08 Tiba Biotech Llc Novel gene delivery agents

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011041897A1 (en) * 2009-10-06 2011-04-14 Angiochem Inc. Compositions and methods for the transport of therapeutic agents

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5258499A (en) 1988-05-16 1993-11-02 Vestar, Inc. Liposome targeting using receptor specific ligands
US5714167A (en) 1992-06-15 1998-02-03 Emisphere Technologies, Inc. Active agent transport systems
EP0599303A3 (en) 1992-11-27 1998-07-29 Takeda Chemical Industries, Ltd. Peptide conjugate
KR19990008458A (ko) 1995-05-08 1999-01-25 쉬어러 피터 알. 쿠니츠(kunitz) 타입 프로테아제 억제 물질
AU5908296A (en) 1995-05-31 1996-12-24 Fred Hutchinson Cancer Research Center Compositions and methods for targeted delivery of effector m olecules
TR199801794T2 (xx) 1996-03-11 2000-07-21 Bayer Corporation �nsan bikunini.
AU729643B2 (en) 1996-05-01 2001-02-08 Antivirals Inc. Polypeptide conjugates for transporting substances across cell membranes
IL131655A0 (en) 1997-03-04 2001-01-28 Bio Technology General Corp Isolation of tissue specific ligands and their use for targeting pharmaceuticals to organs
CA2291074C (en) 1997-05-21 2008-04-01 The Board Of Trustees Of The Leland Stanford Junior University Composition and method for enhancing transport across biological membranes
US6372250B1 (en) 2000-04-25 2002-04-16 The Regents Of The University Of California Non-invasive gene targeting to the brain
JP4202250B2 (ja) 2001-07-25 2008-12-24 バイオマリン ファーマシューティカル インコーポレイテッド 血液脳関門輸送を調節するための組成物および方法
EP1446007A4 (en) 2001-10-16 2005-12-07 Zystor Therapeutics Inc TECHNIQUES AND COMPOSITIONS FOR TARGETING SUBGLYCOSYLATED PROTEINS THROUGH THE HEMATO-ENCEPHALIC BARRIER
JP2005517024A (ja) 2002-02-07 2005-06-09 イッサム リサーチ ディベロプメント カンパニー オブ ザ ヘブリュー ユニバーシティ オブ エルサレム 生物学的障壁を横切る透過を促進し得るアミノ酸配列
US6881829B2 (en) 2002-04-26 2005-04-19 Chimeracom, L.L.C. Chimeric hybrid analgesics
DK1583562T3 (da) 2003-01-06 2011-09-19 Angiochem Inc Angiopep-1, beslægtede forbindelser og anvendelser deraf
AU2003286870A1 (en) 2003-06-05 2005-01-04 Salk Institute For Biological Studies Targeting polypeptides to the central nervous system
US20050026823A1 (en) 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
AU2004253471B2 (en) 2003-06-20 2010-05-13 Raptor Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
EP1652855A4 (en) 2003-08-08 2008-11-19 Tissue Targeting Japan Inc POLYPEPTIDES ACTING ON PREDISPOSITIONS TO BRAIN PATHOLOGIES AND THE USE OF SAID POLYPEPTIDES
US20050058702A1 (en) 2003-09-17 2005-03-17 Ben-Sasson Shmuel A. Compositions capable of facilitating penetration across a biological barrier
EP1796537A4 (en) * 2004-08-25 2012-03-07 Univ Michigan DENDRIMER BASED COMPOSITIONS AND METHOD FOR THEIR USE
US20060078535A1 (en) * 2004-10-13 2006-04-13 The Regents Of The University Of Michigan Anticancer compounds and methods
BRPI0520032A2 (pt) 2005-02-18 2009-04-14 Angiochem Inc moléculas para transportar um composto através da barreira hematoencefálica
US20090016959A1 (en) 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
DK2233156T3 (da) 2005-07-15 2013-08-05 Angiochem Inc Anvendelse af aprotininpolypeptider som bærere i farmaceutiske konjugater
AU2006269879A1 (en) 2005-07-19 2007-01-25 The Board Of Trustees Of The University Of Illinois Transport agents for crossing the blood-brain barrier and into brain cancer cells, and methods of use thereof
US8142781B2 (en) 2005-10-07 2012-03-27 Armagen Technologies, Inc. Fusion proteins for blood-brain barrier delivery
WO2008046228A1 (en) 2006-10-19 2008-04-24 Angiochem, Inc. Compounds for stimulating p-glycoprotein function and uses thereof
CA2688344C (en) 2007-05-29 2019-09-03 Angiochem, Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
CN101946001A (zh) 2007-12-20 2011-01-12 安吉奥开米公司 多肽-核酸结合物及其应用
AU2009238187B2 (en) 2008-04-18 2014-03-06 Angiochem Inc. Pharmaceutical compositions of paclitaxel, paclitaxel analogs or paclitaxel conjugates and related methods of preparation and use
CA2740317A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Etoposide and doxorubicin conjugates for drug delivery
CA2740316A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Conjugates of glp-1 agonists and uses thereof
WO2010063123A1 (en) 2008-12-05 2010-06-10 Angiochem Inc. Leptin and leptin analog conjugates and uses thereof
CA2745499A1 (en) 2008-12-05 2010-06-10 Angiochem Inc. Peptide therapeutic conjugates and uses thereof
CA2745524C (en) 2008-12-05 2020-06-09 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
BRPI0922611A2 (pt) 2008-12-17 2018-11-06 Angiochem Inc inibidores de metaloproteína de matriz de membrana tipo 1 e usos dos mesmos
US20110318322A1 (en) 2009-01-12 2011-12-29 Nektar Therapeutics Conjugates of a Lysosomal Enzyme Moiety and a Water Soluble Polymer
US9173891B2 (en) 2009-04-20 2015-11-03 Angiochem, Inc. Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
US20100284921A1 (en) 2009-05-08 2010-11-11 Temple University - Of The Commonwealth System Of Higher Education Targeted nanoparticles for intracellular cancer therapy
EP2440581A4 (en) 2009-06-11 2013-03-27 Angiochem Inc FUSION PROTEINS FOR THE DELIVERY OF GDNF AND BDNF TO THE CENTRAL NERVOUS SYSTEM
EP2448965A4 (en) 2009-07-02 2015-02-11 Angiochem Inc MULTIMEPEPTID CONJUGATES AND ITS USES
HUE026708T2 (en) 2009-07-14 2016-07-28 Mayo Foundation Peptide-mediated, non-covalent delivery of active substances in blood glucose
US8530429B2 (en) 2009-11-24 2013-09-10 Arch Cancer Therapeutics, Inc. Brain tumor targeting peptides and methods
US9095541B2 (en) 2009-11-24 2015-08-04 Arch Cancer Therapeutics, Inc. Brain tumor targeting peptides and methods
EP2333074A1 (en) 2009-12-14 2011-06-15 Robert Steinfeld Substances and methods for the treatment of lysosmal storage diseases
WO2011153642A1 (en) 2010-06-10 2011-12-15 Angiochem Inc. Leptin and leptin analog conjugates and fusion proteins and uses thereof
AU2011274229A1 (en) * 2010-07-02 2013-01-10 Angiochem Inc. Short and D-amino acid-containing polypeptides for therapeutic conjugates and uses thereof
CN102406949B (zh) 2010-09-21 2013-05-29 复旦大学 一种靶向示踪的多模式诊断纳米影像药物
WO2012037687A1 (en) * 2010-09-23 2012-03-29 Angiochem Inc. Therapeutic polypeptides and uses thereof
CN102552928A (zh) 2010-12-19 2012-07-11 复旦大学 一种治疗脑部肿瘤的双级靶向递药系统及其制备方法
CN102614105A (zh) 2011-01-28 2012-08-01 复旦大学 一种脑靶向载两性霉素b聚合物胶束给药系统
WO2013056096A1 (en) 2011-10-13 2013-04-18 Angiochem Inc. Polypeptide-opioid conjugates and uses thereof
US20150037311A1 (en) 2011-12-01 2015-02-05 Angiochem Inc. Targeted lysosomal enzyme compounds
BR112014013250A2 (pt) 2011-12-01 2019-09-24 Angiochem Inc compostos com enzima alvo e usos dos mesmos
CN104662151A (zh) 2012-06-15 2015-05-27 安吉奥开米公司 靶向的艾杜糖醛酸酶化合物
CN104781281A (zh) 2012-08-14 2015-07-15 安吉奥开米公司 包含抗体部分、穿过血脑屏障的多肽和细胞毒素的结合物
CA2881602A1 (en) 2012-08-14 2014-02-20 Angiochem Inc. Peptide-dendrimer conjugates and uses thereof
CN105026432A (zh) 2012-11-12 2015-11-04 安吉奥开米公司 抑肽酶衍生的多肽-抗体缀合物
GB201220474D0 (en) 2012-11-14 2012-12-26 Sagetis Biotech Sl Polypeptides
US20150290341A1 (en) 2012-11-30 2015-10-15 Anglachem Inc. Targeted iduronate-2-sulfatase compounds
EP3004140A4 (en) 2013-06-06 2017-01-25 Angiochem Inc. Targeted enzyme compounds and uses thereof
WO2014194428A1 (en) 2013-06-06 2014-12-11 Angiochem Inc. Targeted heparan sulfatase compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011041897A1 (en) * 2009-10-06 2011-04-14 Angiochem Inc. Compositions and methods for the transport of therapeutic agents

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KRIS C. WOOD ET AL: "A Family of Hierarchically Self-Assembling Linear-Dendritic Hybrid Polymers for Highly", 《ANGEW. CHEM. INT. ED.》 *
SHIXIAN HUANG ET AL: "Dual targeting effect of Angiopep-2-modified, DNA-loaded nanoparticles for glioma", 《BIOMATERIALS》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106854231A (zh) * 2015-12-09 2017-06-16 中国科学院大连化学物理研究所 一种硫巯化多肽的富集方法
CN106854231B (zh) * 2015-12-09 2020-08-11 中国科学院大连化学物理研究所 一种硫巯化多肽的富集方法
CN117363697A (zh) * 2023-10-10 2024-01-09 上海烈冰生物医药科技有限公司 一种用于核酸捕获的高密度探针磁珠制备方法

Also Published As

Publication number Publication date
US9687561B2 (en) 2017-06-27
EP2885318A4 (en) 2016-03-30
WO2014026283A1 (en) 2014-02-20
JP2015526434A (ja) 2015-09-10
EP2885318A1 (en) 2015-06-24
CA2881602A1 (en) 2014-02-20
AU2013302270A1 (en) 2015-03-26
US20160015823A1 (en) 2016-01-21

Similar Documents

Publication Publication Date Title
CN104781276A (zh) 肽-树枝状聚合物结合物及其用途
JP6355563B2 (ja) Ｘｔｅｎ共役組成物およびそれを製造する方法
JP5759379B2 (ja) ニューロテンシンまたはニューロテンシンアナログおよびその使用
US20170326233A1 (en) Conjugates including an antibody moiety, a polypeptide that traverses the blood-brain barrier, and a cytotoxin
CN110229216B (zh) 具有改善的药代动力学性质的坎普他汀类肽
US20170281787A1 (en) Conjugates including an antibody moiety, a polypeptide that traverses the blood-brain barrier, and a cytotoxin
ES2855169T3 (es) Conjugados de polipéptido-anticuerpo derivados de aprotinina
WO2013056096A1 (en) Polypeptide-opioid conjugates and uses thereof
US20200157151A1 (en) Peptide compounds, conjugate compounds and uses thereof for treating inflammatory diseases
US10213476B2 (en) Compstatin analogs with improved potency and pharmacokinetic properties
CN106163569B (zh) 活化的神经降压素分子及其用途
WO2020056989A1 (zh) 改进型齐考诺肽
US10913780B2 (en) Conjugates, their compositions, their uses, and their methods of making
JP2021536499A (ja) 血液脳関門を通過することができるポリペプチド
WO2020056985A1 (zh) 一种齐考诺肽和tat肽的融合多肽
US20240052005A1 (en) Improved cell-penetrating peptides and fusion proteins
AU2005265425A1 (en) Compositions for multi-step delivery of Hot-Spots radiation to cancer cells
WO2025206033A1 (ja) ｕＰＡＲ結合性ＨＬＨペプチド、ペプチド－薬物複合体および組成物
WO2024131844A1 (zh) 包含莰醇和肽的缀合物及其用途
CN118240010A (zh) 用于治疗中枢神经系统损伤的包含莰醇和肽的缀合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
EXSB Decision made by sipo to initiate substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150715